From the Duke University School of Medicine, Duke University Health System, Durham, North Carolina, USA.
Exp Clin Transplant. 2020 Feb;18(1):93-97. doi: 10.6002/ect.2018.0238. Epub 2019 Apr 9.
Transplant immunosuppression increases the risk of cutaneous squamous cell carcinoma by 65- to 200-fold. Our objective was to investigate the impact of the type of organ transplanted on the risk and presentation of cutaneous squamous cell carcinoma.
The retrospective database of the Duke University Health System was queried to identify patients who underwent an organ transplant from 1996 to 2016. Data regarding transplant outcomes, cutaneous squamous cell carcinoma, immunosuppressive regimens, and survival were recorded. We used chi-square tests, analysis of variance, and unpaired t tests to compare the incidence and presentation of cutaneous squamous cell carcinoma among organ types.
Of 3652 renal, hepatic, and cardiothoracic transplant patients identified, 142 patients developed at least 1 cutaneous squamous cell carcinoma. The incidence of cutaneous squamous cell carcinoma varied by type of organ transplanted, with 46 of 1684 (2.7%) renal transplant patients developing cutaneous squamous cell carcinoma, 33 of 804 (4.1%) hepatic transplant patients, and 63 of 1164 (5.4%) cardiothoracic transplant patients over the median follow-up time of 6.5 years. Incidence in the renal transplant versus the cardiothoracic transplant group was significantly different (P < .001). The time to presentation of cutaneous squamous cell carcinoma varied significantly by group, with the renal cohort presenting at 3.8 years compared with at 2.4 years in the cardiothoracic group and 2.1 years in the hepatic group (P < .001).
The type of organ transplanted confers a unique risk and presentation of cutaneous squamous cell carcinoma.
移植免疫抑制会使皮肤鳞状细胞癌的风险增加 65 至 200 倍。我们的目的是研究所移植的器官类型对皮肤鳞状细胞癌的风险和表现的影响。
通过查询杜克大学健康系统的回顾性数据库,确定了 1996 年至 2016 年期间接受器官移植的患者。记录了与移植结果、皮肤鳞状细胞癌、免疫抑制方案和生存有关的数据。我们使用卡方检验、方差分析和独立样本 t 检验来比较不同器官类型的皮肤鳞状细胞癌的发生率和表现。
在确定的 3652 例肾、肝和心肺移植患者中,有 142 例患者至少发生了 1 例皮肤鳞状细胞癌。皮肤鳞状细胞癌的发生率因所移植的器官类型而异,1684 例肾移植患者中有 46 例(2.7%)、804 例肝移植患者中有 33 例(4.1%)和 1164 例心肺移植患者中有 63 例(5.4%)在中位随访时间 6.5 年内发生了皮肤鳞状细胞癌。肾移植组与心肺移植组的发生率差异有统计学意义(P<0.001)。皮肤鳞状细胞癌的表现时间也因组而异,肾移植队列的表现时间为 3.8 年,而心肺移植队列的表现时间为 2.4 年,肝移植队列的表现时间为 2.1 年(P<0.001)。
所移植的器官类型赋予了皮肤鳞状细胞癌独特的风险和表现。